logo
I attended the world's biggest cancer conference. Doctors gave standing ovations to 2 major breakthroughs.

I attended the world's biggest cancer conference. Doctors gave standing ovations to 2 major breakthroughs.

The biggest cancer conference in the world — ASCO — wrapped up earlier this month in Chicago.
Stunning new data suggested exercise, if done the right way, can be a colon cancer treatment.
AstraZeneca was a perennial star, with new uses for its drugs in early-stage disease.
Recently, I landed on what felt like another planet. Planet cancer research.
Technically, this planet was within the city of Chicago, inside the biggest convention center in North America, McCormick Place, which straddles two sides of a highway. It was filled to the brim with premier cancer experts from around the world.
At the American Society of Clinical Oncology (ASCO) annual meeting, 44,000 doctors, drugmakers, scientists, and patients, gathered both in person and online, spent four days collecting, sharing, and debating the best ways to prevent, treat, and attack cancer.
There were two big announcements that rose above the rest and brought attendees to their feet, cheering and clapping in appreciation.
Doctors were buzzing afterwards, with a few telling me they were inspired to think about new ways to treat their cancer patients. Both breakthroughs pave the way towards a smarter, more targeted future for treating and preventing all kinds of cancer.
1. Exercise outperformed expensive chemo in a groundbreaking trial
There was one talk at ASCO this year that stunned, invigorated, and even angered some doctors.
A team of Canadian scientists showed that a methodically-prescribed exercise routine, performed consistently three to four times per week, could outperform ongoing chemotherapy treatments for patients who'd had colon cancer and gone through initial treatment.
"This is so new and different and really incredible," Dr. Paul Oberstein, a medical oncologist specializing in gastrointestinal cancers at NYU Langone, told Business Insider at the conference.
Doctors routinely recommend exercise to their cancer patients, but there hasn't been a rigorous scientific trial studying the effects. Until now.
The researchers, from Queens University in Ontario, studied nearly 900 colon cancer patients in a gold-standard randomized trial. Each patient's cancer had been removed, and they'd gone through chemotherapy. The goal of the exercise program was to prevent high-risk stage 2 and stage 3 colon cancer from coming back, and to keep the patients alive.
Half of the patients, a control group, were given the same exercise advice that cancer patients often hear from their doctors.
The other half were written an exercise prescription. They were given a trainer or physical therapist who designed a personalized exercise regimen that each patient liked, and that they were likely to stick with for the three-year study. Some kayaked, others biked or swam, but most of the patients (median age of 61) embarked on just a few more walks each week — 45 to 60 minutes at a brisk pace.
After three years of prescribed, sustained exercise, patients saw results that were just as good as — in some cases better than — disease-free survival rates for the chemotherapy drugs that are typically used to treat cancer in this same context, to prevent recurrence. Oxaliplatin is a common colon cancer chemotherapy drug which costs $3,000 to $6,000 per treatment — cheap in the context of cancer care. The drug delivers an overall 10-year survival boost of 5%. The exercise program? 7% survival boost after eight years.
Patients who were just given the fitness advice had significantly more cancer recurrence, and more deaths than the exercise group.
"For every 16 patients exercising, exercise prevented one case of cancer," Chris Booth, a medical oncologist and the lead researcher of the study, said while presenting his results at ASCO. "For every 14 people that were on the exercise program, exercise prevented one person from dying."
Doctors attending ASCO were stunned. After Booth's presentation, a surge of excitement simmered through the crowd of oncologists. A standing ovation began slowly, then swelled to thunderous and enthusiastic sustained applause.
Some of the attendees wondered if this strategy could ever work for their own patients. Could they ever really be motivated to make this kind of change?
For Booth, the study provides a powerful lesson.
"Knowledge alone is likely to be insufficient to allow most people to make meaningful and sustained change," Booth said.
Exercise needs to be treated like a drug, he said. A prescription needs to be filled out, a trainer allotted, and a schedule adhered to.
Oberstein, the NYU Langone oncologist, told Business Insider that the panel had a profound impact on him. He's already talking internally about how his cancer center could implement this kind of program, perhaps with grants from major cancer philanthropy groups or patient support groups who would be willing to pay for tools like wearable trackers and virtual trainer sessions.
"It's a lot easier to get a drug that costs $200,000 a year," Oberstein said. "Than to get insurance or someone to pay for a trainer to help someone do exercise."
2. AstraZeneca's new immunotherapy drug stole the show
The other big insight in cancer treatment that shone through at ASCO was in immunotherapy. Doctors and drugmakers are starting to use these drugs to harness the immune system against earlier-stage cancers, with promising results.
The star of the show was drugmaker AstraZeneca, which had an impressive slate of top-level plenary talks geared toward using drugs earlier on for breast, gastric, and lung cancer survival.
The biggest splash I saw was from AstraZeneca's drug Imfinzi (durvalumab), which trains a patient's body to attack a protein in their cancer. Imfinzi's already routinely used in some late-stage, recurrent and metastatic cancers (in the treatment of solid lung and liver tumors, for example), but it hasn't been a go-to treatment for earlier-stage cancers.
In results from the company's late-stage phase-3 "Matterhorn" trial presented at the conference, Imfinzi, taken with chemo after surgery, boosted gastric cancer patients' two-year survival rates from 70% (without the immunotherapy) to nearly 76% — a significant jump.
The news — just one of AstraZeneca's big wins at the conference — highlights a growing trend in cancer treatment. Increasingly, drugmakers are pursuing early immune therapy treatments. These treatments can either complement — or even, in rare cases, completely replace — radiation and chemotherapy. The goal is to minimize the lifelong side effects of toxic cancer treatment (like lifelong organ damage and fertility issues) while also improving treatment outcomes.
In April, doctors at Memorial Sloan Kettering published results showing a monoclonal antibody treatment that's typically reserved for advanced-stage mismatch repair-deficient rectal tumors can completely replace chemo in earlier stages of disease.
"What was amazing, and is still amazing, is that all the patients in the rectal group had a complete response to just immunotherapy," Dr. Andrea Cercek, a medical oncologist at MSK, told BI during ASCO. "Everyone's organs were completely preserved — very minimal toxicity."
AstraZeneca senior vice president Mohit Manrao, head of the company's US oncology program, told BI that he envisions immunotherapy treatment as a great complement to traditional cancer treatment. Old-school treatments like chemotherapy and radiation go after cancer directly, aiming to kill cancer cells, while the newer drugs "engage the immune system to do better work."
"We cannot just keep treating metastatic cancer patients," Manrao told BI. "We've got to ensure, yes, we serve them, but we need to start getting into early disease where the possibility to cure is really, really high."
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

New Niagara Falls attraction reaches for the stars
New Niagara Falls attraction reaches for the stars

Hamilton Spectator

time29 minutes ago

  • Hamilton Spectator

New Niagara Falls attraction reaches for the stars

They've brought you to see the animals in Africa and Australia, digitally. Now, the owners of Hologram Zoo Niagara want to send you to space. The Space Experience is an immersive installation that brings visitors to the stars using the same holographic technology as the virtual zoo, which opened in June. Developed by Australian-based company Axiom Holographics, the attraction will create the illusion of travelling at warp speed, visiting the International Space Station and seeing a supernova up close, along with projections of the eight planets. It's at the same location as the Hologram Zoo — the corner of Victoria Avenue and Bender Street, across from Casino Niagara. Owner Marty Speelman says it's the first of several themed shows coming to the venue. 'The plan was always that every four or five months to introduce a new show,' he says. 'There's always revolving content. There's a Halloween show coming, a Christmas show coming, seasonal content as well.' As visitors walk through the attraction, motion-tracked projections and layered lighting create a sense of movement and depth around them. It makes people feel part of the environment, not just passersby, says Speelman. 'You do things like go through the tail of comet, see a star being born, you do a space walk, all those kinds of things.' While designing it, Axiom consulted with astronomers and science educators for accuracy. A narrator explains what people are seeing without 'overwhelming' detail. Speelman says the Hologram Zoo is off to a solid start, despite its location away from the main tourist hub. 'Everyone who comes through has been loving it,' he says. 'The challenge for us is, we're not on Clifton Hill. We're a couple-minute walk away. It's just getting people to know that we're there. 'We have a mix of social media marketing and we have a staff person out on the street handing out flyers.' Axiom's head of Canadian business development, John Jackson, says there are plans to open between 30 and 40 hologram zoos throughout Canada. The Space Experience is making its Canadian debut in Niagara Falls. Admission to the Space Experience is $19.99 to $24.99, with combo prices available for both attractions.

AstraZeneca's US Investment, Future of Psychedelic Therapy
AstraZeneca's US Investment, Future of Psychedelic Therapy

Bloomberg

time2 hours ago

  • Bloomberg

AstraZeneca's US Investment, Future of Psychedelic Therapy

On today's episode of Bloomberg Businessweek Daily with Tim Stenovec and Carol Massar, Pascal Soriot, Chief Executive Officer of AstraZeneca discusses the company's quarterly earnings. Kabir Nath, Chief Executive Officer of Compass Pathways, on the pursuit of FDA approval of the first psychedelic treatment for certain people living with depression. Also, Bloomberg's Molly Smith and Oliver Crook on US-China Trade talks and the FOMC meeting (Source: Bloomberg)

Cardiff Oncology Reports Second Quarter 2025 Results and Provides Business Update
Cardiff Oncology Reports Second Quarter 2025 Results and Provides Business Update

Yahoo

time2 hours ago

  • Yahoo

Cardiff Oncology Reports Second Quarter 2025 Results and Provides Business Update

- Appointed Dr. Roger Sidhu as Chief Medical Officer - - Completed enrollment in randomized Phase 2 CRDF-004 trial evaluating onvansertib + standard of care for the treatment of first-line RAS-mutated metastatic colorectal cancer ('mCRC') - - Announced positive data from investigator-initiated trial of onvansertib in combination with paclitaxel in mTNBC at ASCO 2025 - - Cash and investments of $71.0 million as of June 30, 2025, projected runway into Q1 2027 - - Company to hold a conference call today at 4:30 p.m. ET/1:30 p.m. PT to share updated clinical data from the CRDF-004 trial - SAN DIEGO, July 29, 2025 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced financial results for the second quarter ended June 30, 2025, and provided a business update. 'In the second quarter, we achieved an important milestone by completing enrollment in our ongoing CRDF-004 trial evaluating onvansertib plus standard of care for the treatment of first-line RAS-mutated mCRC,' said Mark Erlander, Chief Executive Officer of Cardiff Oncology. 'As we evolve into a late-stage clinical development company, we were excited to appoint Dr. Sidhu as our new Chief Medical Officer to provide expert guidance in advancing onvansertib through the registrational phase of development. We're pleased to welcome him to the team and are confident that his expertise will be instrumental as we work toward bringing this potential therapy to patients.' Conference Call and Webcast on Clinical Data from Ongoing CRDF-004 Trial in mCRC Cardiff Oncology will host a live conference call and webcast at 4:30 p.m. ET/1:30 p.m. PT on July 29, 2025 to share clinical data from the ongoing CRDF-004 trial in first-line RAS-mutated mCRC. Individuals interested in listening to the live conference call may do so by using the webcast link in the "Investors" section of the company's website at A replay will be available in the investor relations section on the company's website following the completion of the call. Company highlights for the quarter ended June 30, 2025, and subsequent weeks include: Appointed Dr. Roger Sidhu as Chief Medical Officer In June 2025, the company appointed Roger Sidhu, MD, as Chief Medical Officer. Dr. Sidhu is a veteran executive and clinician with over 20 years of experience and a strong track record of success in oncology research, development, and regulatory strategy. Announced positive data from investigator-initiated trial of onvansertib in combination with paclitaxel in metastatic triple negative breast cancer (mTNBC) at the American Society of Clinical Oncology (ASCO) Annual Meeting 2025 The Phase 1b study of onvansertib in combination with paclitaxel in mTNBC was led by Antonio Giordano, MD, PhD at Dana-Farber Cancer Institute, a principal teaching affiliate of Harvard Medical School. Onvansertib in combination with paclitaxel demonstrated a 40% objective response rate (ORR) by RECIST 1.1 at RP2D of 18mg/m2 (n=10), with two confirmed partial responses and two unconfirmed partial responses. The combination was well-tolerated and demonstrated a safe and manageable toxicity profile with myelosuppression being the most common adverse event. Overall, this clinical data further supports the potential exploration of the combination of onvansertib plus paclitaxel for the treatment of mTNBC. Announced a second patent issuance from the United States Patent and Trademark Office (USPTO) for the treatment of mCRC for bev-naïve patients U.S. patent No. 12,263,173 has an expiration date of no earlier than 2043. The claims of the new patent cover the method of using onvansertib in combination with bev in any line of therapy for the treatment of mCRC patients who have not previously been treated with bev. The newly issued patent encompasses all mCRC patients, with RAS-mutated or RAS wild-type mCRC. Announced completion of enrollment in Phase 2, randomized, CRDF-004 trial evaluating onvansertib + standard of care (SoC) for the treatment of first-line RAS-mutated mCRC The Phase 2 CRDF-004 trial reached the targeted enrollment of patients with first-line mCRC across 41 clinical sites in the U.S. The Company is holding a conference call today to share an update on the ongoing trial. Second Quarter 2025 Financial Results: Liquidity, cash burn, and cash runway As of June 30, 2025, Cardiff Oncology had approximately $71.0 million in cash, cash equivalents, and short-term investments. Net cash used in operating activities for the second quarter of 2025 was approximately $8.3 million, a decrease of $0.9 million from $9.2 million for the same period in 2024. Based on its current expectations and projections, the Company believes its current cash resources are sufficient to fund its operations into Q1 2027. Operating results Total operating expenses were approximately $14.9 million for the three months ended, June 30, 2025, an increase of $2.2 million from $12.7 million for the same period in 2024. The increase in operating expenses was primarily due to costs associated with our CRDF-004 clinical trial, other clinical programs and outside service costs related to the development of our lead drug candidate, onvansertib, as well as salaries and wages for key hires and additional stock option grants. About Cardiff Oncology, Inc. Cardiff Oncology is a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers. The Company's lead asset is onvansertib, a PLK1 inhibitor being evaluated in combination with standard of care (SoC) therapeutics in clinical programs targeting indications such as RAS-mutated metastatic colorectal cancer (mCRC), as well as in ongoing and planned investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma (mPDAC), small cell lung cancer (SCLC) and metastatic triple negative breast cancer (mTNBC). These programs and the Company's broader development strategy are designed to target tumor vulnerabilities in order to overcome treatment resistance and deliver superior clinical benefit compared to the SoC alone. For more information, please visit Forward-Looking Statements Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified using words such as "anticipate," "believe," "forecast," "estimated" and "intend" or other similar terms or expressions that concern Cardiff Oncology's expectations, strategy, plans or intentions. These forward-looking statements are based on Cardiff Oncology's current expectations and actual results could differ materially. There are several factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, clinical trials involve a lengthy and expensive process with an uncertain outcome, and results of earlier studies and trials may not be predictive of future trial results; our clinical trials may be suspended or discontinued due to unexpected side effects or other safety risks that could preclude approval of our product candidate; results of preclinical studies or clinical trials for our product candidate could be unfavorable or delayed; our need for additional financing; risks related to business interruptions, including the outbreak of COVID-19 coronavirus and cyber-attacks on our information technology infrastructure, which could seriously harm our financial condition and increase our costs and expenses; uncertainties of government or third party payer reimbursement; dependence on key personnel; limited experience in marketing and sales; substantial competition; uncertainties of patent protection and litigation; dependence upon third parties; and risks related to failure to obtain FDA clearances or approvals and noncompliance with FDA regulations. There are no guarantees that our product candidate will be utilized or prove to be commercially successful. Additionally, there are no guarantees that future clinical trials will be completed or successful or that our product candidate will receive regulatory approval for any indication or prove to be commercially successful. Investors should read the risk factors set forth in Cardiff Oncology's Form 10-K for the year ended December 31, 2024, and other periodic reports filed with the Securities and Exchange Commission. While the list of factors presented here is considered representative, no such list should be considered to be a complete statement of all potential risks and uncertainties. Unlisted factors may present significant additional obstacles to the realization of forward-looking statements. Forward-looking statements included herein are made as of the date hereof, and Cardiff Oncology does not undertake any obligation to update publicly such statements to reflect subsequent events or circumstances. Cardiff Oncology Contact:James LevineChief Financial Officer858-952-7670jlevine@ Investor Contact:Kiki Patel, PharmDGilmartin Group332-895-3225kiki@ Media Contact:Meghan BiancoTaft Cardiff Oncology, Statements of Operations(in thousands, except for per share amounts)(unaudited) Three Months Ended June 30, Six Months Ended June 30, 2025 2024 2025 2024 Royalty revenues $ 121 $ 163 $ 230 $ 368 Costs and expenses: Research and development 11,580 9,493 22,057 17,501 Selling, general and administrative 3,318 3,215 7,332 6,345 Total operating expenses 14,898 12,708 29,389 23,846 Loss from operations (14,777 ) (12,545 ) (29,159 ) (23,478 ) Other income (expense), net: Interest income, net 835 805 1,776 1,731 Other income (expense), net (1 ) (38 ) 6 (42 ) Total other income (expense), net 834 767 1,782 1,689 Net loss (13,943 ) (11,778 ) (27,377 ) (21,789 ) Preferred stock dividend (6 ) (6 ) (12 ) (12 ) Net loss attributable to common stockholders $ (13,949 ) $ (11,784 ) $ (27,389 ) $ (21,801 ) Net loss per common share — basic and diluted $ (0.21 ) $ (0.26 ) $ (0.41 ) $ (0.49 ) Weighted-average shares outstanding — basic and diluted 66,526 44,825 66,525 44,752 Cardiff Oncology, Balance Sheets(in thousands)(unaudited) June 30,2025 December 31,2024 Assets Current assets: Cash and cash equivalents $ 10,784 $ 51,470 Short-term investments 60,173 40,276 Accounts receivable and unbilled receivable 526 773 Prepaid expenses and other current assets 2,213 2,535 Total current assets 73,696 95,054 Property and equipment, net 743 898 Operating lease right-of-use assets 899 1,169 Other assets 401 69 Total Assets $ 75,739 $ 97,190 Liabilities and Stockholders' Equity Current liabilities: Accounts payable $ 6,010 $ 4,821 Accrued liabilities 9,938 7,897 Operating lease liabilities 721 710 Total current liabilities 16,669 13,428 Operating lease liabilities, net of current portion 464 813 Total Liabilities 17,133 14,241 Stockholders' equity 58,606 82,949 Total liabilities and stockholders' equity $ 75,739 $ 97,190 Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store